ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

“Leadership Vacuum: At NCI Allows NIH To Look At Reorganization, Varmus Says

November 4, 1994

Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors

April 29, 2011

Greenwald: Report’s Implementation Will Require Budget Raise

June 27, 1997

DCBDC board Okays RFA concept On AIDS Lymphoma

March 26, 1993

New ACS Grants to Fund ‘Critical, Urgent’ Research

April 15, 1977

Tight Budget, Turf Battles Kill One Project, Threaten Popular CGP Clinical Trials Effort

July 4, 1986